← Russell 3000 cross-section

QURE uniQure N.V.

Trailing twelve months to 2026-03-31 · as filed 2026-05-05, not restated
Healthcare

Scale

Market cap
$3.5bn
Revenue TTM
$18m
Net income TTM
$-209m
Free cash flow
$-173m
Composite score
25.4
Sector rank
#1308

Valuation

P / E
EV / EBITDA
EV / sales
187.6
FCF yield
-4.95%
Earnings yield vs 10-yr
-10.73pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-1,154.4%
EBITDA margin
ROE
-139.9%
ROIC
-323.4%
Revenue growth
-10.4%

Insider activity, last 90 days

Net open-market
$-16.82m
Buyers
0
Sellers
11

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The increase was driven by changes to the discount rate and expected timing of future achievement of the related remaining milestones. The decrease in collaboration revenue in 2025 of $10.7 million compared to 2024 was primarily related to a reduction in services requested by CSL Behring following the Lexington Transaction in July 2024 . The increase in collaboration revenue in 2024 of $8.6 million compared to 2023 was primarily related to additional development and other services provided in relation to the transfer of manufacturing responsibility to CSL Behring. ​ 97 ​ Table of Contents We provided contract manufacturing services to CSL Behring between April 2022 and July 2024. …uniQure N.V., 10-K, period ended 2025-12-31, filed 2026-03-02

Read the full passage →